| Index | — | P/E | 18.42 | EPS (ttm) | 0.48 | Insider Own | — | Shs Outstand | 4.40B | Perf Week | -12.30% |
| Market Cap | 38.88B | Forward P/E | 14.62 | EPS next Y | 0.60 | Insider Trans | — | Shs Float | 4.42B | Perf Month | 0.23% |
| Enterprise Value | 48.65B | PEG | 2.51 | EPS next Q | 0.38 | Short Float | 0.42% | Perf Quarter | -11.16% | ||
| Income | 2.17B | P/S | 2.61 | EPS this Y | 12.76% | Short Ratio | 1.26 | Perf Half Y | -3.60% | ||
| Sales | 14.90B | P/B | 1.80 | EPS next Y | 7.47% | ROA | 4.98% | Short Interest | 18.54M | Perf YTD | -12.56% |
| Book/sh | 4.92 | P/C | 35.76 | EPS next 5Y | 7.34% | ROE | 9.89% | 52W High | 11.28 -21.63% | Perf Year | -4.64% |
| Cash/sh | 0.25 | P/FCF | 14.22 | EPS past 3/5Y | 17.12% 9.07% | ROIC | 6.46% | 52W Low | 8.38 5.49% | Perf 3Y | 13.62% |
| Dividend Est. | 0.13 (1.46%) | EV/EBITDA | 12.35 | Sales past 3/5Y | 2.85% 2.79% | Gross Margin | 65.57% | Volatility | 2.20% 1.74% | Perf 5Y | — |
| Dividend TTM | 0.20 (2.24%) | EV/Sales | 3.26 | EPS Y/Y TTM | — | Oper. Margin | 21.35% | ATR (14) | 0.27 | Perf 10Y | — |
| Dividend Ex-Date | Aug 14, 2026 | Quick Ratio | 0.52 | Sales Y/Y TTM | — | Profit Margin | 14.55% | RSI (14) | 37.34 | Recom | 2.25 |
| Dividend Gr. 3/5Y | — | Current Ratio | 0.69 | EPS Q/Q | 13.59% | SMA20 | -8.09% | Beta | -0.08 | Target Price | 10.20 |
| Payout | 39.00% | Debt/Eq | 0.50 | Sales Q/Q | 3.50% | SMA50 | -6.82% | Rel Volume | 1.90 | Prev Close | 8.76 |
| Employees | 24,535 | LT Debt/Eq | 0.38 | Earnings | Mar 04 | SMA200 | -9.38% | Avg Volume | 16.78M | Price | 8.84 |
| IPO Date | Jul 25, 2022 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 23.73% 16.89% | Net Debt/EBITDA | 2.48 | Volume | 31,814,840 | Change | 0.91% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jan-23-26 | Upgrade | Barclays | Equal Weight → Overweight | |
| Sep-16-25 | Downgrade | Barclays | Overweight → Equal Weight | |
| Jan-10-25 | Reiterated | Morgan Stanley | Overweight | $9.15 → $10 |
| Apr-08-24 | Reiterated | Morgan Stanley | $9.15 | |
| Apr-06-23 | Upgrade | Argus Research | Hold → Buy |
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 14,905 | 14,561 | 14,354 | 14,053 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 5,135 | 5,059 | 5,475 | 5,398 | — | — | — | — | |
| Gross Profit | 9,769 | 9,224 | 8,878 | 8,655 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 5,888 | 5,761 | 5,537 | 5,332 | — | — | — | — | |
| Research and Development | 414 | 407 | 381 | 387 | — | — | — | — | |
| Other Operating Expense | 0 | -321 | 141 | 455 | — | — | — | — | |
| Operating Income | 3,468 | 3,184 | 2,819 | 2,482 | — | — | — | — | |
| Interest Expense | 424 | 439 | 503 | 515 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -194 | 96 | 125 | 57 | — | — | — | — | |
| Net Income Before Taxes | 2,851 | 2,841 | 2,441 | 2,024 | — | — | — | — | |
| Income Taxes | 664 | 609 | 556 | 643 | — | — | — | — | |
| Consolidated Net Income | 2,167 | 2,152 | 1,843 | 1,304 | — | — | — | — | |
| Net Income From Continuing Operations | 2,186 | 2,169 | 1,885 | 1,381 | — | — | — | — | |
| Net Income | 2,167 | 2,152 | 1,843 | 1,304 | — | — | — | — | |
| EPS (Recurring) | 0.48 | 0.48 | 0.41 | 0.30 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.48 | 0.48 | 0.41 | 0.30 | — | — | — | — | |
| EPS (Diluted) | 0.48 | 0.48 | 0.41 | 0.30 | — | — | — | — | |
| EBITDA | 3,938 | 3,801 | 3,376 | 2,923 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 18.42 | 21.27 | 23.33 | 27.58 | — | — | — | — | |
| Price To Sales Ratio | 2.64 | 3.11 | 3.03 | 2.71 | — | — | — | — | |
| Gross Margin | 65.54 | 63.35 | 61.85 | 61.59 | — | — | — | — | |
| Operating Margin | 23.27 | 21.87 | 19.64 | 17.66 | — | — | — | — | |
| Net Margin | 14.54 | 14.78 | 12.84 | 9.28 | — | — | — | — | |
| Shares Outstanding | 4,443 | 4,481 | 4,566 | 4,632 | — | — | — | — | |
| Market Capitalization | 39,276 | 45,303 | 43,560 | 38,121 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |